Last year, the biotech sector was less profitable than in 2005, with the total net loss expanding by more than one-third. Revenue grew by 14% to $73.5 billion but R&D expenses also jumped 33% to ∼$28 billion. About one-third of US public firms have solid financial positions, with more than five years of cash. Deal making and mergers accelerated, with high premiums for early-stage technology. The number of biotech firms reached 4,275, with public companies accounting for only 17%.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lawrence, S. State of the biotech sector—2006. Nat Biotechnol 25, 706 (2007). https://doi.org/10.1038/nbt0707-706
Issue Date:
DOI: https://doi.org/10.1038/nbt0707-706
